Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 3

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---

  
    Accounts payable and accrued liabilities 
     936,992  
     (2,705,402)
  
    Net cash used in operating activities 
     (2,847,051) 
     (5,873,884)

    Cash flows from investing activities: 

    Purchases of investment securities 
     -  
     (105,949)
  
    Proceeds from sale and maturity of investment securities 
     -  
     2,500,000 
  
    Purchases of property and equipment 
     (259,652) 
     (11,755)
  
    Net cash (used in) provided by investing
    activities 
     (259,652) 
     2,382,296 

    Cash flows from financing activities: 

    Proceeds from sale of common stock equity, net of issuance costs 
     105,692  
     - 
  
    Net cash provided by financing activities 
     105,692  
     - 

    Net change in cash and cash equivalents 
     (3,001,011) 
     (3,491,588)
  
    Cash and cash equivalents at beginning of period 
     5,872,767  
     5,838,566 
  
    Cash and cash equivalent at end of period 
    $2,871,756  
    $2,346,978 

See accompanying notes to the unaudited condensed
consolidated financial statements.

5

IMUNON, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

FOR THE THREE MONTHS ENDED MARCH 31, 2025

    Common Stock Outstanding  
    Additional Paid-in  
    Treasury Stock  
    Accumulated  
    Total Stockholders’ 

    Shares  
    Amount  
    Capital  
    Shares  
    Amount  
    Deficit  
    Equity 

    Balance at January 1, 2025 
     14,500,707  
    $145,007  
    $410,987,523  
     22  
    $(85,188)-
    $(406,803,044) 
    $4,244,298 

    Net loss 
     -  
     -  
     -